美女免费一级视频在线观看

    • <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Amneal Pharmaceuticals is launching an initiative to establish a community for people with Parkinson’s disease as well as their caregivers. 
      




      The Thrive initiative will build upon an existing newsletter that focuses on patient stories and resources.
      




      The goal of the expansion is to “reach a broader group within the Parkinson’s disease community to educate patients and their loved ones, helping them thrive with their diagnosis,” Amneal noted in a statement. 
      




      The motivation behind the expansion was a “reaction to the need within the community to connect and find valuable resources and education,” the company added.
      




      The initiative includes a new website and Facebook page that offers information on how patients can “thrive” with their current treatment for the degenerative disease and “thrive with fewer daily doses.” 
      




      Additionally, the initiative will feature patient stories and articles that offer recipes, non-medication therapy and other tips for living with Parkinson’s, as well as support for caregivers.
      




      Amneal has been active in the Parkinson’s space for a while, most recently banking on its novel carbidopa/levodopa (CD/LD) extended-release capsule drug, IPX203. 
      




      In November, the company announced that the Food and Drug Administration had accepted the new drug application (NDA) for IPX203, calling it an “important milestone.”
      




      “We believe the data in our RISE-PD study supports the important benefit IPX203 can offer to this community by providing longer duration of symptom control with the benefit of fewer doses,” noted Gustavo Pesquin, chief commercial officer at Amneal Specialty, in a statement at the time.
      




      The RISE-PD trial showed IPX203 was able to manage Parkinson’s symptoms for longer periods of time – and with less frequent dosing than prior treatments.
      




      Additionally, the RISE-PD data indicated IPX203 can offer patients an important treatment option that will enable them to have more “‘good on’ time during the day,” according to Chintu Patel, co-CEO at Amneal. 
      




      “We are working with the FDA to bring this treatment to market,” he said in a statement.
      




      Amneal also recently released its fourth quarter and full year 2022 earnings, reporting an increase of 14% in net revenue in the fourth quarter, and a 6% increase in net revenue between 2021 and 2022. 
      




      The company cited its “new innovations in generics,” and its injectables portfolio as being part of the driver for growth.